[Sulbactam-ampicillin in surgery. Our experience].

Area of Science:

• Surgery
• Infectious Diseases
• Pharmacology

Background:

• Bacterial infections pose significant challenges in surgical settings.
• Appropriate antibiotic selection, guided by sensitivity testing, is crucial for effective treatment.
• Sulbactam-ampicillin (Unasyn) is a combination antibiotic comprising a beta-lactamase inhibitor and ampicillin.

Purpose of the Study:

• To evaluate the efficacy and safety of sulbactam-ampicillin (Unasyn) in treating bacterial infections in post-digestive surgery patients.
• To assess the clinical outcomes of Unasyn in patients with intra-abdominal infections, wound infections, and subphrenic abscesses.

Main Methods:

• A prospective study involving 21 hospitalized patients with confirmed bacterial infections after digestive surgery.
• Administration of sulbactam-ampicillin (Unasyn) at daily dosages of 3-12 g, divided into 3-4 doses, administered via slow intravenous infusion.
• Identification of causative organisms including Staphylococcus epidermidis, Staphylococcus aureus, Serratia, Streptococcus, and E. coli.

Main Results:

• A 100% success rate was achieved in treating bacterial infections among the study cohort.
• No systemic or local side effects were reported during the treatment period.
• The antibiotic susceptibility of isolated organisms guided the dosage and treatment duration.

Conclusions:

• Sulbactam-ampicillin (Unasyn) demonstrates high efficacy and an excellent safety profile for treating surgical site infections.
• The study supports the use of Unasyn as a reliable therapeutic option for complex bacterial infections in surgical patients.
• Further research could explore broader applications and comparative effectiveness against other antibiotic regimens.